Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens.

  title={Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens.},
  author={Leighton J Seal and Sheeba Franklin and Catherine Richards and A Shishkareva and Carole Sinclaire and James Barrett},
  journal={The Journal of clinical endocrinology and metabolism},
  volume={97 12},
CONTEXT Breast development in transwomen is an important issue, affecting general psychological functioning. Current hormonal therapies are imperfect, with 60% of patients requesting mammoplasty. INTERVENTIONS Interventions included the following: 1) comparing the effects on transwomen's requests for mammoplasty of estrogen valerate, ethinylestradiol, and conjugated equine estrogen (CEE) hormone treatments; and 2) comparing the effects of GnRH analogs and androgen antagonists. OBJECTIVE The… 

Management of endocrine disease: Optimal feminizing hormone treatment in transgender people.

Evidence is discussed regarding established and upcoming feminizing treatment for adult transgender women or for gender non-binary people seeking feminization, with special focus on the pharmacotherapy of feminizing hormonal therapy.

Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study

It is shown that, after 1 year of CHT, breast development is modest and occurs primarily in the first 6 months, and no clinical or laboratory parameters were found that predict breast development.

Venous Thrombotic Risk in Transgender Women Undergoing Estrogen Therapy: A Systematic Review and Metaanalysis.

The study estimated the incidence rate of venous thromboembolism in transgender women prescribed estrogen to be 2.3 per 1000 person-years, but because of heterogeneity this estimate cannot be reliably applied to transgender women as a group.

Risks of sex hormone therapy in women: important lessons from the transgender woman literature.

Clinicians should consider falling in line with the general principle of endocrine therapy, which is to replace the missing hormone (17A-estradiol, or E2, in the context of any hypogonadal female) wherever possible.

Safety of hormonal treatment in transgenders

Treatment must be highly individualized and transitioning patients need to be engaged in a ‘clinical contract’ with the physician in order to ensure compliance with prescribed treatments.

Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy

The data suggest that the route of hormone administration, patient demographics, and patient comorbidities all affect estrogen’s link with VTE, and Clinicians should avoid the use of ethinyl estradiol and progestins should be avoided for transgender individuals.



Augmentation mammaplasty in male-to-female transsexuals.

The basic anatomic and surgical considerations of augmentation mammaplasty for 201 male-to-female transsexuals who were operated on from 1979 to 1997 are reviewed and discussed.

Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.

The range of treatment used by transsexual people, the rationale behind these, and the expectation from such treatment are discussed, as well as the potential adverse effects of cross-sex hormone treatment of transsexual people.

Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.

It is concluded that cross-sex hormone treatment of male-to-female transsexuals using GnRHa and oestradiol-17beta valerate is effective, and side effects and complication rates can be reduced using the treatment regimen presented here.

Physical and hormonal evaluation of transsexual patients: A longitudinal study

Based on the data generated by this study, it is recommended as hormonal therapy 0.1–0.5 mg/day of ethinyl estradiol or 7.5–10 mg/ day of conjugated estrogen for male-to-female transsexuals, and intramuscular testosterone cypionate, 200 mg every 2 weeks, for female- to-male transsexuals.

Long-term assessment of the physical, mental, and sexual health among transsexual women.

Transsexual women function well on a physical, emotional, psychological and social level, but sexual functioning as assessed through FSFI was suboptimal when compared with biological women, especially the sublevels concerning arousal, lubrication, and pain.


This treatment caused a significant decrease in the severity of the hirsutism after only three months, the effect being maximal after six months, suggesting that one facet in the favorable action of cyproterone acetate is an inhibition of the action of androgen on target cells.

Hormonal therapy and sex reassignment: a systematic review and meta‐analysis of quality of life and psychosocial outcomes

The prognosis of individuals with gender identity disorder (GID) receiving hormonal therapy as a part of sex reassignment in terms of quality of life and other self‐reported psychosocial outcomes is assessed.

Long‐term follow‐up of bone mineral density and bone metabolism in transsexuals treated with cross‐sex hormones

It is unknown whether long term cross‐sex hormone treatment affects the human skeleton, and bone mineral density and biochemical markers of bone turnover in male‐to‐female transsexuals treated with anti‐androgens and oestrogens and those treated with androgens are monitored.

Oestradiol assays: fitness for purpose?

To make oestradiol assays fit for purpose requires concerted action by all stakeholders to define analytical quality specifications for the various clinical scenarios involved, and then by the diagnostic industry to use the steroid reference measurement system to improve specificity, trueness and traceability.


  • H. FreyA. Aakvaag
  • Medicine, Biology
    Acta obstetricia et gynecologica Scandinavica
  • 1981
Women with essential hirsutism with cyclic administration of cyproterone acetate and ethinyl estradiol were treated with these drugs for one year with biochemical and clinical control after 1, 3, 6 and 12 months of treatment.